Addex Therapeutics (ADXN) Net Income towards Common Stockholders: 2022-2025
Historic Net Income towards Common Stockholders for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to -$1.8 million.
- Addex Therapeutics' Net Income towards Common Stockholders fell 112.49% to -$1.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.6 million, marking a year-over-year increase of 269.50%. This contributed to the annual value of $8.0 million for FY2024, which is 168.24% up from last year.
- According to the latest figures from Q2 2025, Addex Therapeutics' Net Income towards Common Stockholders is -$1.8 million, which was down 172.44% from -$653,016 recorded in Q1 2025.
- Over the past 5 years, Addex Therapeutics' Net Income towards Common Stockholders peaked at $14.2 million during Q2 2024, and registered a low of -$11.9 million during Q4 2023.
- Over the past 3 years, Addex Therapeutics' median Net Income towards Common Stockholders value was -$2.0 million (recorded in 2023), while the average stood at -$287,250.
- As far as peak fluctuations go, Addex Therapeutics' Net Income towards Common Stockholders crashed by 213.96% in 2023, and later soared by 578.65% in 2024.
- Addex Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$3.8 million in 2022, then plummeted by 213.96% to -$11.9 million in 2023, then skyrocketed by 167.68% to $8.1 million in 2024, then tumbled by 112.49% to -$1.8 million in 2025.
- Its Net Income towards Common Stockholders stands at -$1.8 million for Q2 2025, versus -$653,016 for Q1 2025 and $8.1 million for Q4 2024.